Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12

Sonnet BioTherapeutics, Inc.

Companies Mentioned:

Primary Exchange: NASDAQ
Under the Symbol: SONN

$2.78

($0.2700)

-8.8525


Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12

Monday, July 20, 2020 7:30 AM
  • Data provide proof-of-concept for advancing SON-2014, a bispecific combination of GMcSF and IL-18
  • The company will further explore the utility of a bispecific combination of GMcSF and IL-12

PRINCETON, NJ / ACCESSWIRE / July 20, 2020 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing innovative targeted biologic drugs with enhanced mono or bispecific mechanisms, announced today that it has completed initial preclinical proof-of-concept work with both GMcSF and IL-18 and with GMcSF and IL-12 in a xenograft mouse model of melanoma. This study was designed to evaluate preclinical activity of the concomitantly administered cytokines as FHAB-derived molecules, using Sonnet's Fully Human Albumin Binding (FHAB) technology, in several groups of tumor-bearing mice. Sonnet's FHAB-derived drug candidates all showed statistically significant reduction in tumor growth compared to placebo and when compared to cytokines not derived from the Company's platform.

The study included nine mice per active group and 12 mice in the placebo group. The Company administered a single dose as a conservative method for therapeutic lead selection. The table below summarizes the data after six days of administration of a single dose, in tumor bearing mice with an average initial cancer tumor volume of approximately 100 mm3. P values were generated for between group comparisons (treatment vs placebo) of reduction in tumor growth.

Constructs - Day 6 Data

Dose (µg)

Mean Tumor Volume, mm3

STD

P value*

Placebo

-

1136

278

 

GMcSF

5

848

282

NS

GMcSF-FHAB

1

739

236

0.0021

IL-18

5

665

187

<0.0001

IL18-FHAB

1

480

179

<0.0001

GMcSF-FHAB + IL12-FHAB

1+1

435

108

<0.0001

GMcSF-FHAB + IL18-FHAB

2+2

678

176

<0.0001

* Using Tukey-Kramer HSD method

       

The data indicate that GMcSF-FHAB and IL18-FHAB administered as monospecific formulations demonstrated improved anti-tumor activity (slower tumor progression) as compared with naked GMcSF or naked IL-18. In both comparisons, the FHAB-derived molecules showed similar activity at one fifth the dose level as compared to naked, wild type cytokine. The Company also evaluated its IL12-FHAB to investigate optimal synergies for future bispecific combinations. The data indicate that co-injection of GMcSF-FHAB and IL12-FHAB as monospecifics resulted in a strong synergistic reduction in tumor growth with just a single dose. Importantly, for all groups that received FHAB-derived candidates, there was no weight loss observed, which potentially implies reduced toxicity relative to treatment with naked cytokine. Further animal studies are planned to optimize combinations for CMC development.

Pankaj Mohan, Ph.D., Founder and CEO, commented that, "We are very excited about these data, which suggest that GMcSF and IL-18 carry great promise as anti-cancer compounds, and encourage Sonnet's continued development of our bispecific candidate, SON-2014. This study also expands on the work we have done with SON-1010 and SON-1210 and augments our efforts to build a comprehensive immune oncology pipeline." He further commented that, "there is a level of consistency from our FHAB platform showing higher activity at lower doses when compared to naked molecules. We believe that the key characteristic of our technology, which leads to the enhanced activity we are seeing, is the FHAB's albumin binding for improved pK and tumor targeting."

John Cini, Ph.D., Co-Founder and CSO commented that, "I continue to be encouraged by these additional FHAB platform data, which demonstrate a consistent ability to enhance positive activity across all drug candidates tested thus far, including GMcSF and IL-18. GMcSF has been shown in the literature to have a significant impact on cancer cells by the local recruitment and activation of dendritic cells, resulting in the amelioration of tumor antigen-presentation to T cells. IL-18 has been shown in the literature to transport T cells from the lymphatic system to the tumor micro-environment, thereby promoting the transformation of a ‘cold tumor' into a 'hot tumor'."

About Sonnet BioTherapeutics, Inc.

Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitchhikes" on human serum albumin (HSA) for transport to target tissues. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Sonnet Biotherapeutics Investor Contact
Alan Lada
Solebury Trout
617-221-8006
[email protected]

SOURCE: Sonnet BioTherapeutics, Inc.


Subscribe to alerts from Investor Network
SHARE ARTICLE